CN115484983A - 一种重组抗pd-1单克隆抗体的稳定制剂 - Google Patents

一种重组抗pd-1单克隆抗体的稳定制剂 Download PDF

Info

Publication number
CN115484983A
CN115484983A CN202180032307.8A CN202180032307A CN115484983A CN 115484983 A CN115484983 A CN 115484983A CN 202180032307 A CN202180032307 A CN 202180032307A CN 115484983 A CN115484983 A CN 115484983A
Authority
CN
China
Prior art keywords
antibody
amino acid
acid sequence
seq
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180032307.8A
Other languages
English (en)
Other versions
CN115484983B (zh
Inventor
胡萍
刘艳
孙春昀
淮庆茹
田绍美
陶明珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinocelltech Ltd
Original Assignee
Sinocelltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinocelltech Ltd filed Critical Sinocelltech Ltd
Publication of CN115484983A publication Critical patent/CN115484983A/zh
Application granted granted Critical
Publication of CN115484983B publication Critical patent/CN115484983B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供一种重组单克隆抗体的稳定制剂。由重组抗PD‑1单克隆抗体、缓冲液、渗透压调节剂、稳定剂和表面活性剂组成。所述药物制剂可增强抗体的稳定性，延长其在含水制剂中的有效期。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180032307.8A 2020-06-19 2021-06-17 一种重组抗pd-1单克隆抗体的稳定制剂 Active CN115484983B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020105661538 2020-06-19
CN202010566153 2020-06-19
PCT/CN2021/100658 WO2021254447A1 (zh) 2020-06-19 2021-06-17 一种重组抗pd-1单克隆抗体的稳定制剂

Publications (2)

Publication Number Publication Date
CN115484983A true CN115484983A (zh) 2022-12-16
CN115484983B CN115484983B (zh) 2024-05-24

Family

ID=79268518

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032307.8A Active CN115484983B (zh) 2020-06-19 2021-06-17 一种重组抗pd-1单克隆抗体的稳定制剂

Country Status (10)

Country Link
US (1) US20230272106A1 (zh)
EP (1) EP4169530A1 (zh)
JP (1) JP2023529234A (zh)
KR (1) KR20230026446A (zh)
CN (1) CN115484983B (zh)
AU (1) AU2021292116A1 (zh)
BR (1) BR112022025721A2 (zh)
CA (1) CA3180463A1 (zh)
MX (1) MX2022015733A (zh)
WO (1) WO2021254447A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107743401A (zh) * 2015-04-17 2018-02-27 百时美施贵宝公司 包含抗pd‑1抗体和另外的抗体的组合的组合物
CN109498565A (zh) * 2018-12-27 2019-03-22 兴盟生物医药(苏州)有限公司 一种稳定的抗pd-1抗体制剂及其用途
CN109562173A (zh) * 2016-08-09 2019-04-02 信达生物制药(苏州)有限公司 Pd-1抗体制剂
CN110404066A (zh) * 2018-04-28 2019-11-05 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
CN110787292A (zh) * 2020-01-06 2020-02-14 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途
CN110869002A (zh) * 2017-05-02 2020-03-06 默沙东公司 程序性死亡受体1(pd-1)抗体的稳定制剂及其使用方法
WO2020097139A1 (en) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106390115A (zh) * 2015-07-29 2017-02-15 上海君实生物医药科技股份有限公司 一种人源化单克隆抗体的稳定制剂
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN111349162A (zh) * 2018-12-21 2020-06-30 神州细胞工程有限公司 人源化抗pd-1抗体及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107743401A (zh) * 2015-04-17 2018-02-27 百时美施贵宝公司 包含抗pd‑1抗体和另外的抗体的组合的组合物
CN109562173A (zh) * 2016-08-09 2019-04-02 信达生物制药(苏州)有限公司 Pd-1抗体制剂
CN110869002A (zh) * 2017-05-02 2020-03-06 默沙东公司 程序性死亡受体1(pd-1)抗体的稳定制剂及其使用方法
CN110404066A (zh) * 2018-04-28 2019-11-05 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2020097139A1 (en) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN109498565A (zh) * 2018-12-27 2019-03-22 兴盟生物医药(苏州)有限公司 一种稳定的抗pd-1抗体制剂及其用途
CN110787292A (zh) * 2020-01-06 2020-02-14 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAI XING等: "Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia", COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol. 25, 31 December 2022 (2022-12-31), pages 1399 - 1410 *
郭雯 等: "创新药专利精解", 31 August 2021, 知识产权出版社, pages: 308 *

Also Published As

Publication number Publication date
BR112022025721A2 (pt) 2023-01-03
US20230272106A1 (en) 2023-08-31
KR20230026446A (ko) 2023-02-24
CA3180463A1 (en) 2021-12-23
EP4169530A1 (en) 2023-04-26
AU2021292116A1 (en) 2023-01-05
JP2023529234A (ja) 2023-07-07
WO2021254447A1 (zh) 2021-12-23
MX2022015733A (es) 2023-01-18
CN115484983B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
US20220175916A1 (en) Methods and compositions for treating chronic effects of radiation and chemical exposure
CA2910065C (en) Purification of recombinantly produced polypeptides
EP3250594B1 (en) Anti-transthyretin antibodies
JP2020185009A (ja) 抗トランスサイレチン抗体
TWI554284B (zh) 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
EP3250593B1 (en) Anti-transthyretin antibodies
CN110538322A (zh) 抗体配制剂
TW201643197A (zh) 針對ｔａｕ之抗體及其用途
CN106029682B (zh) 等电点低的抗体的纯化方法
JP2020535167A (ja) 抗ｐａｃａｐ抗体
JP2024037881A (ja) Ｃ末端抗体改変体
CN115484983B (zh) 一种重组抗pd-1单克隆抗体的稳定制剂
WO2023120561A1 (ja) 生物活性が低下した抗体バリアント
JP2023159309A (ja) 生物活性が低下した抗体バリアント
EP4011390A1 (en) Preparation comprising anti-pd-1/her2 bispecific antibody, and preparation method therefor and use thereof
CN116271016A (zh) 一种SARS-CoV-2中和抗体的稳定制剂
KR102677203B1 (ko) 항-트랜스타이레틴 항체
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
KR20230053012A (ko) 항-pd-1 항체를 포함하는 암의 치료용 약학적 조성물
KR20190126103A (ko) 아벨루맙을 포함하는 조성물
CN112675300A (zh) 包含抗gitr抗体的制剂及其制备方法和用途
CN117731771A (zh) 液体抗体组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077279

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant